The Clinical Observation of Inflammation Theory for Depression: The Initiative of the Formosa Long COVID Multicenter Study (FOCuS)

키워드

참고문헌 (71)

1. Sivan M, "NICE guideline on long covid", BMJ, 371, pp.m4938~ (2020)
2. Venkatesan P, "NICE guideline on long COVID", Lancet Respir Med, 9, pp.129~ (2021)
3. Soriano JB, "A clinical case definition of post-COVID-19 condition by a Delphi consensus", Lancet Infect Dis, 22, pp.e102~e107 (2022)
4. Desai AD, "Long-term complications of COVID-19", Am J Physiol Cell Physiol, 322, pp.C1~ (2022)
5. Nalbandian A, "Post-acute COVID-19 syndrome", Nat Med, 27, pp.601~615 (2021)
6. Crook H, "Long covidmechanisms, risk factors, and management", BMJ, 374, pp.n1648~ (2021)
7. Liang CS, "Unresolved systemic inflammation, long COVID, and the common pathomechanisms of somatic and psychiatric comorbidity", J Clin Med, 11, pp.5114~ (2022)
8. Sykes DL, "Post-COVID-19 symptom burden : what is long-COVID and how should we manage it?", Lung, 199, pp.113~119 (2021)
9. Seeßle J, "Persistent symptoms in adult patients 1 year after coronavirus disease 2019(COVID-19) : a prospective cohort study", Clin Infect Dis, 74, pp.1191~1198 (2022)
10. "A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020and 2021" (2022)[URL]
11. Taquet M, "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection : an analysis of 2-year retrospective cohort studies including 1 284 437 patients", Lancet Psychiatry, 9, pp.815~827 (2022)
12. Miskowiak KW, "Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation : pattern, severity, and functional implications", Eur Neuropsychopharmacol, 59, pp.82~92 (2022)
13. Thompson EJ, "Long COVID burden and risk factors in 10UK longitudinal studies and electronic health records", Nat Commun, 13, pp.3528~ (2022)
14. Angeles MR, "Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan", BMC Public Health, 22, pp.757~ (2022)
15. Solmi M, "Physical and mental health impact of COVID-19 on children, adolescents, and their families : The Collaborative Outcomes study on Health and Functioning during Infection Times-Children and Adolescents(COH-FIT-C&A)", J Affect Disord, 299, pp.367~376 (2022)
16. Solmi M, "The collaborative outcomes study on health and functioning during infection times in adults(COH-FITAdults) : design and methods of an international online survey targeting physical and mental health effects of the COVID-19pandemic", J Affect Disord, 299, pp.393~407 (2022)
17. Vanderlind WM, "A systematic review of neuropsychological and psychiatric sequalae of COVID-19 : implications for treatment", Curr Opin Psychiatry, 34, pp.420~433 (2021)
18. Rogers JP, "Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections : a systematic review and meta-analysis with comparison to the COVID-19pandemic", Lancet Psychiatry, 7, pp.611~627 (2020)
19. Llach CD, "Mind long COVID : psychiatric sequelae of SARS-CoV-2 infection", Eur Neuropsychopharmacol, 49, pp.119~121 (2021)
20. Bourmistrova NW, "Long-term effects of COVID-19 on mental health : a systematic review", J Affect Disord, 299, pp.118~125 (2022)
21. Khraisat B, "Meta-analysis of prevalence : the psychological sequelae among COVID-19 survivors", Int J Psychiatry Clin Pract, 26, pp.234~243 (2022)
22. Mazza MG, "Post-COVID-19 depressive symptoms : epidemiology, pathophysiology, and pharmacological treatment", CNS Drugs, 36, pp.681~702 (2022)
23. COVID-19 Mental Disorders Collaborators, "Global prevalence and burden of depressive and anxiety disorders in 204countries and territories in 2020 due to the COVID-19pandemic", Lancet, 398, pp.1700~1712 (2021)
24. "Long-term psychological consequences of long COVID: a propensity score matching analysis comparing trajectories of depression and anxiety symptoms before and after contracting long COVID vs short COVID" (2022)[URL]
25. Johnson SU, "Psychiatric symptoms in COVID-19-positive individuals in the general population : trajectories of depression, anxiety, and insomnia", Psychiatry Res, 317, pp.114806~ (2022)
26. Gruber J, "Mental health and clinical psychological science in the time of COVID-19 : challenges, opportunities, and a call to action", Am Psychol, 76, pp.409~426 (2021)
27. Adhanom Ghebreyesus T, "Addressing mental health needs : an integral part of COVID-19 response", World Psychiatry, 19, pp.129~130 (2020)
28. Taquet M, "Bidirectional associations between COVID-19 and psychiatric disorder : retrospective cohort studies of 62 354 COVID-19 cases in the USA", Lancet Psychiatry, 8, pp.130~140 (2021)
29. Kim SW, "Using psychoneuroimmunity against COVID-19", Brain Behav Immun, 87, pp.4~5 (2020)
30. Bliźniewska-Kowalska KM, "A review of the global impact of the COVID-19 pandemic on public mental health, with a comparison between the USA, Australia, and Poland with Taiwan and Thailand", Med Sci Monit, 27, pp.e932220~ (2021)
31. Mazza MG, "Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue", J Psychiatr Res, 155, pp.112~119 (2022)
32. Bottemanne H, "Do anxiety and depression predict persistent physical symptoms after a severe COVID-19 episode? A prospective study", Front Psychiatry, 12, pp.757685~ (2021)
33. Mazza MG, "Persistent psychopathology and neurocognitive impairment in COVID-19 survivors : effect of inflammatory biomarkers at three-month follow-up", Brain Behav Immun, 94, pp.138~147 (2021)
34. Ceban F, "Fatigue and cognitive impairment in Post-COVID-19 syndrome : a systematic review and meta-analysis", Brain Behav Immun, 101, pp.93~135 (2022)
35. Lee CH, "The role of inflammation in depression and fatigue", Front Immunol, 10, pp.1696~ (2019)
36. Semyachkina-Glushkovskaya O, "Brain mechanisms of COVID-19-sleep disorders", Int J Mol Sci, 22, pp.6917~ (2021)
37. Boldrini M, "How COVID-19 affects the brain", JAMA Psychiatry, 78, pp.682~683 (2021)
38. Yang CP, "Long COVID and long chain fatty acids(LCFAs) : psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19", Brain Behav Immun, 103, pp.19~27 (2022)
39. Han QQ, "Inflammation : a mechanism of depression?", Neurosci Bull, 30, pp.515~523 (2014)
40. Miller AH, "The role of inflammation in depression : from evolutionary imperative to modern treatment target", Nat Rev Immunol, 16, pp.22~34 (2016)
41. Beurel E, "The bidirectional relationship of depression and inflammation : double trouble", Neuron, 107, pp.234~256 (2020)
42. Milaneschi Y, "Association of inflammation with depression and anxiety : evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts", Mol Psychiatry, 26, pp.7393~7402 (2021)
43. Osimo EF, "Prevalence of low-grade inflammation in depression : a systematic review and meta-analysis of CRP levels", Psychol Med, 49, pp.1958~1970 (2019)
44. Osimo EF, "Inflammatory markers in depression : a meta-analysis of mean differences and variability in 5, 166 patients and 5, 083 controls", Brain Behav Immun, 87, pp.901~909 (2020)
45. Dantzer R, "From inflammation to sickness and depression : when the immune system subjugates the brain", Nat Rev Neurosci, 9, pp.46~56 (2008)
46. Dooley LN, "The role of inflammation in core features of depression : insights from paradigms using exogenously-induced inflammation", Neurosci Biobehav Rev, 94, pp.219~237 (2018)
47. Gritti D, "Neuroinflammation in major depressive disorder : a review of PET imaging studies examining the 18-kDa translocator protein", J Affect Disord, 292, pp.642~651 (2021)
48. Nettis MA, "Is there neuroinflammation in depression? Understanding the link between the brain and the peripheral immune system in depression", Int Rev Neurobiol, 152, pp.23~40 (2020)
49. Green C, "Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder", Brain Behav Immun, 92, pp.39~48 (2021)
50. Hidese S, "Cerebrospinal fluid inflammatory cytokine levels in patients with major psychiatric disorders : a multiplex immunoassay study", Front Pharmacol, 11, pp.594394~ (2021)
51. Coperchini F, "The cytokine storm in COVID-19 : an overview of the involvement of the chemokine", chemokine-receptor system, 2020, pp.53, 25~32
52. Zhang C, "Cytokine release syndrome in severe COVID-19 : interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality", Int J Antimicrob Agents, 55, pp.105954~ (2020)
53. "Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)" (2020)[URL]
54. Viszlayová D, "SARS-CoV-2 RNA in the cerebrospinal fluid of a patient with long COVID", Ther Adv Infect Dis, 8, pp.20499361211048572~ (2021)
55. Sodagar A, "Pathological features and neuroinflammatory mechanisms of SARS-CoV-2 in the brain and potential therapeutic approaches", Biomolecules, 12, pp.971~ (2022)
56. Pariante CM, "Increased inflammation in depression : a little in all, or a lot in a few?", Am J Psychiatry, 178, pp.1077~1079 (2021)
57. Slavich GM, "From stress to inflammation and major depressive disorder : a social signal transduction theory of depression", Psychol Bull, 140, pp.774~815 (2014)
58. Wang SC, "The three frontlines against COVID-19 : brain, behavior, and immunity", Brain Behav Immun, 93, pp.409~414 (2021)
59. Shields GS, "Psychosocial interventions and immune system function : a systematic review and meta-analysis of randomized clinical trials", JAMA Psychiatry, 77, pp.1031~1043 (2020)
60. Black DS, "Mindfulness meditation and the immune system : a systematic review of randomized controlled trials", Ann N Y Acad Sci, 1373, pp.13~24 (2016)
61. Bower JE, "Mind-body therapies and control of inflammatory biology : a descriptive review", Brain Behav Immun, 51, pp.1~11 (2016)
62. Morgan N, "The effects of mind-body therapies on the immune system : meta-analysis", PLoS One, 9, pp.e100903~ (2014)
63. Guu TW, "International Society for Nutritional Psychiatry Research practice guidelines for Omega-3 fatty acids in the treatment of major depressive disorder", Psychother Psychosom, 88, pp.263~273 (2019)
64. Lin PY, "A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids", J Clin Psychiatry, 68, pp.1056~1061 (2007)
65. Nishi D, "The efficacy of Omega-3 fatty acids for depressive symptoms among pregnant women in Japan and Taiwan : a randomized, double-blind, placebo-controlled trial(SYNCHRO;NCT01948596)", Psychother Psychosom, 88, pp.122~124 (2019)
66. Chiu CC, "Omega-3 polyunsaturated fatty acids for postpartum depression", Am J Obstet Gynecol, 190, pp.582~583 (2004)
67. Su KP, "Association of use of Omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms : a systematic review and meta-analysis", JAMA Netw Open, 1, pp.e182327~ (2018)
68. Chang JP, "Omega-3 fatty acids in the psychological and physiological resilience against COVID-19", Prostaglandins Leukot Essent Fatty Acids, 161, pp.102177~ (2020)
69. Shabbir MA, "Delving the role of nutritional psychiatry to mitigate the COVID-19 pandemic induced stress, anxiety and depression", Trends Food Sci Technol, 120, pp.25~35 (2022)
70. Iddir M, "Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition : considerations during the COVID-19 crisis", Nutrients, 12, pp.1562~ (2020)
71. Singh B, "Do diet and dietary supplements mitigate clinical outcomes in COVID-19?", Nutrients, 14, pp.1909~ (2022)

관련 논문AI추천